Literature DB >> 7987863

Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity.

C Di Lazzaro1, G Digiesi, R Tecce, L V Lotti, M R Torrisi, P G Natali.   

Abstract

Two immunotoxins were prepared using monoclonal antibodies (mAb) directed towards two distinct epitopes of the gp185HER-2 extracellular domain, and the type I ribosome inactivating protein (RIP) plant toxin saporin 6. Cell protein synthesis inhibition assay reveals that the immunotoxins display a potent and specific cytotoxicity that is characterized by a slow rate, since the time required to inhibit incorporation of radiolabeled leucine completely ranges from 36 h to 60 h depending on the target cell line and the immunotoxin. Because this feature may hamper the immunotherapeutic use of these conjugates we analysed this further by studying the early phases of internalization of immunotoxins by immunoelectron microscopy. The results of this study have demonstrated that the distribution pattern of the immunotoxins and of the unconjugated mAb over the cell surface overlaps. Similarly the mAb and immunotoxins are internalized into the cell by two different pathways: via clathrin-coated pits or via smaller uncoated pits and vesicles. A higher degree of internalization is achieved when the two immunotoxins are used in combination. Unlike the slow kinetics of cell intoxication the process of immunotoxin endocytosis is characterized by a rapid rate of internalization (above 40% at 5 min in the SK-BR-3 cell line). Although these findings provide no clue to explain the mechanisms of the slow rate of cytotoxicity of the two immunotoxins their rapid internalization indicates that these reagents can be exploited in immunotherapeutic approaches to gp185HER-2-expressing malignancies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987863     DOI: 10.1007/BF01519985

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit.

Authors:  D Wen; E Peles; R Cupples; S V Suggs; S S Bacus; Y Luo; G Trail; S Hu; S M Silbiger; R B Levy
Journal:  Cell       Date:  1992-05-01       Impact factor: 41.582

2.  Production and characterization of two immunotoxins specific for M5b ANLL leukaemia.

Authors:  R Tecce; R Fraioli; P De Fabritiis; A Sandrelli; A Savarese; L Santoro; M Cuomo; P G Natali
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

5.  Surface distribution and internalization of erbB-2 proteins.

Authors:  L V Lotti; C Di Lazzaro; C Zompetta; L Frati; M R Torrisi
Journal:  Exp Cell Res       Date:  1992-10       Impact factor: 3.905

6.  Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2.

Authors:  G Digiesi; P Giacomini; R Fraioli; M Mariani; M R Nicotra; O Segatto; P G Natali
Journal:  Hybridoma       Date:  1992-08

7.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

8.  Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.

Authors:  B Falini; A Bolognesi; L Flenghi; P L Tazzari; M K Broe; H Stein; H Dürkop; F Aversa; P Corneli; G Pizzolo
Journal:  Lancet       Date:  1992-05-16       Impact factor: 79.321

9.  Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells.

Authors:  M Bregni; D A Lappi; S Siena; A Formosa; S Villa; M Soria; G Bonadonna; A M Gianni
Journal:  J Natl Cancer Inst       Date:  1988-06-01       Impact factor: 13.506

10.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.